Ebixa
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Background Memantine hydrochloride is a N-methyl-D-aspartate (NMDA) antagonist that may be useful in the treatment of Alzheimer's…
In the EU, once-daily memantine 20 mg (Axura®, Ebixa®) is an option for the management of patients with moderate to severe…
Memantin HCL (Ebixa) is a drug which antagonizes the effects of N-methyl-D-aspartat receptors and which is used for the treatment…
Alzheimer’s disease may not yet be curable, but it is treatable. Two classes of drugs with differing mechanisms of action have…
Alzheimer's disease (AD) is the most common etiology of dementia. Its incidence increases with age following an exponential trend…
Alzheimer's disease (AD) is the most common etiology of dementia. Its incidence increases with age following an exponential trend…
Memantine is the first agent licensed for the treatment of moderate to severe Alzheimer's disease. It is an N-methyl D-aspartate…
Severe dementia is a devastating condition causing great impairment in cognition and functional capacity. The costs associated…
Deux etudes randomisees, en double aveugle contre placebo, ont demontre la bonne tolerance et l'efficacite de la memantine dans…
Memantine hydrochloride, an NMDA antagonist, was launched in Germany by Merz in 1989 for the treatment of dementia, an indication…